Study to Evaluate Patients With Cerebrotendinous Xanthomatosis (RESTORE)

计划入组 19 人 · 首次发布于 2020 年 2 月 17 日

Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma

计划入组 54 人 · 首次发布于 2026 年 2 月 6 日

The Resilience Alliance

计划入组 357 人 · 首次发布于 2015 年 8 月 13 日

CTX-1349 + CTX-T19

Perflubron Emulsion(Alliance)

CTx-0262135

ALLIANCE PHARMACEUTICALS

Nepal

ALLIANCE PHARMACEUTICALS LIMITED

United Kingdom

ALLIANCE MEDICAL LIMITED

United Kingdom

FDA Approves First Treatment for Cerebrotendinous Xanthomatosis (CTX), Offering Hope to Patients with Rare Genetic Disorder

Compass Therapeutics' CTX-471 Shows Promise with NCAM Biomarker Correlation in Advanced Malignancies

FDA Clears Path for Cingulate's CTx-1301 ADHD Treatment NDA Submission